1. The possibility today for someone to use his own stem cells throughout the whole course of his/her life is 1:200, Nietfeld et al 2008, Bio Blood Marrow Transl 14 (3), 316-322. This analogy in 1997 only for patients who suffered from the hematopoietic system diseases and for ages under 20 years old was 74:200000. According to a study of the University of Arizona today one in three patients over 60 may benefit from the new applications of stem cells with his own cells for the therapy of cardiovascular, ophthalmologic, orthopedic, neurologic and endocrine diseases, Harris et al; 2007, Exper Opin Biol Biological Therapy 7 (9), 1311.
2. From 1995 the blood of the umbilical cord has the same therapeutic applications as bone marrow, Jenney et al 1995, Lancet 346 (8980), 921-2, with more however advantages that derive from the young age of these cells.
3. From 2006 according to the announcement of the European Group for Blood and Marrow the blood of the umbilical cord is included in the program of autologous transplantations for the therapy of autoimmune diseases with mentions to juvenile rheumatoid arthritis, lupus erythematosous and multiple sclerosis, Bone marr trans 2006, 37(5):434-449. From the Clinic of Hematology at Papanikolaou Hospital there have been repeatedly published studies in international medical journals for the therapy of multiple sclerosis with the use of stem cells of the patient himself. These studies were refer to Greek patients and to patients from collaborating European countries. The results of this therapy according to these studies are encouraging although the cells of the patients are of greater age and suffer from the disease the moment of the receipt, Kimiskidis et sl 2008, Mult Scler 14 (2): 278-83, Fassas et al 2004, J Neurol Sci 15, 223 (1): 53-8, Fassas et al 2003, J Hematother Stem Cells Res 12(6): 701-11. If the patient had stem cells derived from the umbilical cord blood that he/she should have cryopresreved from the time of his/her birth the results would be better.
4. Until today in Europe there have been performed 25000 transplantations with the use of hematopoietic primary cells. 70% of these transplantations were autologous, the stem cells were derived from the patient himself, and 30% were allogeneic, they were derived from a donor. In the 70% of these cases the donor within the family, Watt et al 2007, Methods Mol Biol 368: 237-259.
5. The therapy of solid malignant tumors of youth (sarcoma, neuroblastomas, lymphomas) is performed with the use of cells of the child himself. The yearly frequency of occurrence of cancer in children is 130 per million, so the probability of a child to present leukemia or cancer until the age of 16 is 1/500 and for 1 in four children a hematopoietic transplantation is required, Smith et al 2002, Principles and Practice of Pediatric Oncology, 4th edition Philadelphia PA Lippincott. The probability of use of the graft is doubled, if one conciders the blood relatives that may make use of the graft.
6. Cancer and leukemia are expressed through a series of mutations in cells that eventually result in carcinogenesis. For the expression of leukemia two continual mutations in the nuclei of hematopoietic stem cells are required. The first mutation results in the formation and circulation in the blood, the preleukemic clones. So if the mutation occurs in the first stages of the development of the embryo prior to birth, then also in the umbilical cord blood preleukemic clones will circulate. From 100 cases of children will preleukemic clones eventually only one child will advance to the second mutation and develop leukemia, Mori et al 2002, Proc Natl Acd Sci USA, 99:8242-8247. The preleukemic clones in the rest of the children are eventually destroyed from the immune system and disappeared from the blood circulation. For older children and adults there is no issue of detection of preleukemic clones because even in the hypothetical case of birth of a child with preleukemic clone a great period of time has passes from birth to the onset of the disease and the autologous transplantation will give the patient the same period of survival without the fear of rejection of an allogeneic, and not completely compatible graft. The genes that are responsible or coexist with leukemia can be detected with PCR method on the stem cells and it will lead to the detection of those pathogenic genes and will resolve the problem of the use of the stem cells of the child or not.
In public banking no test is performed for the presence of preleukemic clones in the stem cells of the donor. For the samples that come from unknown donors a test should be performed also for the detection of inherited diseases. If the probability of 1% of a preexisting malignancy in the stem cells of the umbilical cord is considered significant, the public bank would perform the essential tests for the determination of the existence or not of the malignancy in all grafts that it collects.
7. Mesenchymal stem cells from Wharton’s Jelly are collected today only for autologous use and due to their mutual origin with the primary hematopoietic stem cells any transfer of inheritance or mutation in these, concerns also the messenchimal cells. So cryopreservation and autologous transplantation of mesenchymal stem cells of the Warton’s Jelly from the public bank sets under dispute its objection for the autologous administration of hematopoietic stem cells derived from the placenta, in cases of child leukemia.
8. If chemotherapy was the solution for therapy of cancer or leukemia, one of the greater problems in medicine today would be resolved; the therapy of cancer.
9. In 2007 a case of a 3 year old child suffering from acute lymphoblastic leukemia was published. At 2003 chemotherapy failed twice in this child and finally with his own stem cells, that the family had cryopreserved for percussion burring birth in a private bank, Hayani et al 2007, Pediatrics 119, 296-300. Today 4 years post transplantation the child is free of symptoms. In leukemia the total survival among patients that received their own stem cells or allogeneic compatible grafts don’t differ significantly, Loy Ys et al 2007 Leuk Lymphoma , 48 (1), 72-9. So what is the problem if the patient posses his own autograft or a graft compatible from a sibling, because the patients had preserved the umbilical cord blood?
10. Lately there have been posed some journalistic opinions that with one small biopsy of the skin one could have stem cells for use in autologous transplantations. Today for the transformation of the cells of the skin into stem cells an alteration in 4 genes must be performed and also a simultaneous entry of 4 different viruses in the cell, with unexpected results. Gene therapy is not safe neither with the use of just one virus. This kind of therapy was abandoned after the death of children with cystic fibrosis, due to the revival of the virus that had been used for gene therapy. Another reason is that with this way adult cells can be transformed into embryonic with the fear of ignition of tumor genes and the formation of teratomas.
11. The legal guidelines were published in Greece in March 2008 in the presidential order 26/2008. Until the full application of the greek legislation the greek private cryobanks must follow the European legislation and must be certified from greek and international bodies as the national system of certification (ESYD)
12. For many years and even today, stem cells of greek families travel to countries abroad. The foundation of the greek banks and the remain of stem cells in Greece ensures better quality grafts.
13. The uses of stem cells in medicine today refer to all 17 medical specialties and for this reason the validation of the operation of private and public banks the Greek government has assigned the Central Council of Health and not to specific specialties.
President of the Scientific Board of Biohellenika
Dr. Kouzi- Koliakou
